Abstract
Dried blood spot (DBS) metabolite analysis is a central tool for the clinic, e.g. newborn screening. Instead of applying multiple analytical methods, a single liquid chromatography-mass spectrometry (LC-MS) method was developed for metabolites spanning from highly polar glucose to hydrophobic long-chain acylcarnitines. For liquid chromatography, a diphenyl column and a multi-linear solvent gradient operated at elevated flow rates allowed for an even-spread resolution of diverse metabolites. Injecting moderate volumes of DBS organic extracts directly, in contrast to evaporation and reconstitution, provided substantial increases in analyte recovery. Q Exactive MS settings were also tailored for sensitivity increases, and the method allowed for analyte retention time and peak area repeatabilities of 0.1-0.4 % and 2-10 %, respectively, for a wide polarity range of metabolites (logP −4.4 to 8.8). The method’s performance was suited for both untargeted analysis as well as targeted approaches, evaluated in clinically relevant experiments.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Internal funding: Financial support from UiO:Life Science (University of Oslo) is gratefully acknowledged. External funding: This work was also partially supported by the Research Council of Norway through its Centre of Excellence scheme, project number 262613. S.R.W. is a member of the National Network of Advanced Proteomics Infrastructure (NAPI), which is funded by the Research Council of Norway INFRASTRUKTUR-program (project number: 295910).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Approval by Regional Committees for Medical and Health Research Ethics: The use of whole blood from healthy volunteers was approved by the Regional Committees for Medical and Health Research Ethics (case number: 173346). Page to the organization: https://www.med.uio.no/english/about/organization/adm/rec-south-east/
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data presented and described in this manuscript is from liquid chromatography-mass spectrometry recordings. The raw data files are available upon request.
